Pharmacokinetics and pharmacodynamics of zolmitriptan in patients with mild to moderate hypertension: A double-blind, placebo-controlled study

Journal of Clinical Pharmacology

Volumn 38, Issue 8, 1998, Pages 685-693

  Smith, Deborah A ^a   Cleary, Elena W ^a   Watkins, Stephanie ^a   Huffman, Cameron S ^a   Dilzer, Stacy C ^b   Lasseter, Kenneth C ^b  

^a GLAXOSMITHKLINE   (United States)

^b Clinical Pharmacology Associates Miami   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ZOLMITRIPTAN;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD PRESSURE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG TOLERABILITY; FEMALE; HEADACHE; HUMAN; HYPERTENSION; MALE; MIGRAINE; NAUSEA; SEX DIFFERENCE; VASOCONSTRICTION; VERTIGO;

EID: 0031865712     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1002/j.1552-4604.1998.tb04807.x     Document Type: Article

References (16)

1. Plosker GL, McTavish D: Sumatriptan: a reappraisal of its pharmacology and therapeutic efficacy in the acute treatment of migraine and cluster headaches. Drugs 1994:47:622-651.
2. 1D agonist drugs: selectively targeting additional sites of action. Eur Neural 1996:36(suppl 2):13-18.
3. Seaber E, On N, Phillips S, Churchus R, Posner J, Rolan P: The tolerability and pharmacokinetics of the novel antimigraine compound 311C90 in healthy male subjects. Br J Clin Pharmacol 1996;41:141-147.
4. Dixon R, On N, Posner J: High oral bioavailability of the novel 5HT agonist, 311C90 (abstract P16). Cephalalgia 1995;15(suppl 14):218.
5. Seaber E, On N, Dixon RM, Gibbens M, Leavens WJ, Liptrot J, et al: The absolute bioavailability and metabolic disposition of the novel antimigraine compound zolmítríptan (311C90). Br J Clin Pharmacol 1997;43:579-587.
6. 1B/n receptor agonist zolmitriptan (311C90): are brain stem sites therapeutic targets in migraine? Pain 1996;67:355-359.
7. 1D receptor agonist in the acute oral treatment of migraine. Neurology 1996;46:522-526.
8. Dahlöf C, Diener HC, Goadsby PJ, Massiou H, Olesen J, Schoenen J, et al: A multicenter, double-blind, placebo-controlled, dose-range finding study to investigate the efficacy and safety of oral doses of 311C90 in the acute treatment of migraine (abstract). Headache 1995;35:292.
9. Rapoport AM, Cady RK, Mathew NT, Ramadan NM, Taylor SR, Saper JR, et al: Optimizing the oral dose of 311C90 in the acute treatment of migraine (abstract). Cephalalgia 1995;15(suppl 14): 221.
10. Martin GR, MacLennan SJ, Cambridge D, Whiting MV: Effect of 311C90 on regional blood flow and systemic haemodynamics in anaesthetised dogs and cats (abstract 24). Cephalagia 1995; 15(suppl 14):311.
11. Earl NL: Clinical safety of 311C90: aggregated data from patients and subjects to date. Eur Neural 1996;36(suppl 2):8-12.
12. Dixon R, Gillotin C, Gibbens M, Posner J, Peck RW: The pharmacokinetics and effects of blood pressure of multiple doses of the novel anti-migraine drug zolmitriptan (311C90) in healthy volunteers. Br J Clin Pharmacol 1997;43:273-281.
13. McEvoy GK: Diuretics. In. Drug Information. Bethesda, MD: American Society of Health-System Pharmacists, 1995;1776-1780.
14. Giorgi L, Dixon R, Touw K: Cardiovascular safety of the novel anti-migraine compound 311C90 (abstract P18). Cephalalgia 1995;15(suppl 14):220.
15. Lloyd K: The clinical profile of sumatriptan: safety and tolerability. EUT Neural 1994;34(suppl 2):40-43.
16. 1B/1D agonist: international clinical experience based on >3000 subjects treated with zolmitriptan. Cephalalgia 1997; 17(suppl 18):41-52.